Current issue: Clinical Neuropsychiatry - n. 4 - August - 2008
Pharmacoeconomics
Katherine J. Aitchison and Paul McCrone
01 Editorial HOW FAR HAVE WE GOT IN PHARMACOECONOMICS FOR PSYCHIATRY AND WHERE ARE WE GOING? Paul McCrone, Katherine J. Aitchison, David Taylor
02 Paper ALL DRESSED UP AND KNOW WHERE TO GO: AN EXAMPLE OF HOW TO USE NET BENEFIT REGRESSION TO DO A COST-EFFECTIVENESS ANALYSIS WITH PERSON-LEVEL DATA (THE ‘A’ IN CEA) Jeffrey S. Hoch
03 Paper RETURNING TO THE ISSUE OF THE COST-EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA Ruth I. Ohlsen, David Taylor, Kopal Tandon, Katherine J. Aitchison
04 Paper ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE USE PATTERNS, AND COSTS IN PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES Martin Knapp, Paul McCrone, Oscar Leeuwenkamp
05 Paper PHARMACOGENETIC TESTING IN PSYCHIATRY: PHARMACOECONOMIC APPLICATIONS AND CONSIDERATIONS Renee Romeo, Katherine J. Aitchison, Delphine Capdevielle
PDFs of these articles are all freely downloadable at www.clinicalneuropsychiatry.org or by clicking on the above links.
Friday, 9 January 2009
Subscribe to:
Posts (Atom)